ヒトメタニューモウイルス診断の市場規模、シェア、動向分析レポート：技術別、最終用途別、地域別、セグメント予測、2025年～2030年

ヒトメタニューモウイルス（hMPV）診断市場の成長と動向

Grand View Research, Incの最新レポートによると、世界のヒトメタニューモウイルス診断市場規模は2030年までに9億7,130万米ドルに達すると予測され、2025～2030年にかけてCAGR 10.43％で成長すると予測されています。

ヒトメタニューモウイルス診断市場は、特に小児、高齢者、免疫不全者などの脆弱な集団の間で、hMPVによる呼吸器感染症の流行が増加していることを背景に、大きな成長を遂げています。hMPVは、気管支炎、肺炎、上気道感染症など、インフルエンザや呼吸器合胞体ウイルス（RSV）によるものと同様の呼吸器疾患を引き起こすことが知られています。呼吸器疾患におけるhMPVの役割に対する認識が高まるにつれ、効果的な診断ソリューションに対する需要が高まり、市場の拡大に寄与しています。

この市場の主要促進要因としては、診断技術の進歩、医療支出の増加、hMPV感染の早期かつ正確な検出に対する需要の高まりなどが挙げられます。また、特に温暖な気候の地域でウイルス性呼吸器感染症が増加していることも、成長を後押しする大きな要因となっています。さらに、PCRベースのアッセイ、抗原ベースの検査、マルチプレックスPCRプラットフォームなどの迅速診断検査の開発が進んでいるため、より迅速な検出が可能であり、これは患者の予後を改善し、感染拡大を抑制するために極めて重要です。

hMPV診断市場は競争が激しく、複数の有力企業がその成長に貢献しています。主要市場参入企業には、Abbott Laboratories、Roche Diagnostics、Thermo Fisher Scientific、BioMerieux、Siemens Healthineersなどがあります。これらの企業は、hMPVをより効率的に検出するための新しい診断ツールやプラットフォームの開発に積極的に取り組んでいます。戦略的提携、買収、研究開発投資は、製品ポートフォリオの拡大とプレゼンスの向上に役立っています。

最近の市場動向は、ポイントオブケア検査や複数の病原体を同時に検出できるマルチプレックス分子検査など、より高度で迅速、かつ費用対効果の高い診断法へのシフトを強調しています。これらの技術革新は、特に資源が限られた環境において、効率的な診断法に対する需要の高まりに対応する上で極めて重要です。市場はまた、ハイリスク患者群に不可欠なタイムリーな治療決定を支援するため、より迅速な結果を提供する検査開発にますます注力しています。

hMPV感染の有病率は世界的に上昇しており、特に5歳以下の小児や高齢者、免疫力の低下した患者において顕著です。このウイルスは、呼吸器疾患による入院の相当数の原因となっており、公衆衛生上の重大な懸念となっています。正確でタイムリーな診断は、効果的な管理のために極めて重要であり、診断ソリューションの採用拡大がhMPV診断市場の将来を形成し続けると予想されます。

ヒトメタニューモウイルス診断市場レポートハイライト

• 技術別では、PCRベースの診断セグメントが2024年に54.97%の最大売上シェアを占め、その高精度、高感度、低ウイルス量の検出能力が牽引しています。PCRアッセイは、感染の初期段階でも迅速かつ信頼性の高いhMPVの検出を可能にし、迅速な診断、患者の転帰改善、特に高リスク集団におけるウイルス感染の抑制強化につながります。
• 最終用途別では、専門的な検査、より迅速な診断結果、より正確な疾患検出に対する需要の増加により、診断とレファレンス検査室セグメントが予測期間中に最も速いCAGRで成長すると予想されます。これらの検査室は、hMPVやその他の呼吸器感染症を特定するために不可欠なサービスを提供し、臨床と研究の両セグメントをサポートしています。
• 地域別では、北米市場が世界市場全体を支配し、2024年には41.18％の売上シェアを占めました。これは、高い認知度、先進的医療インフラ、呼吸器感染症の有病率の増加によるものです。
• ヒトメタニューモウイルス診断市場の競合シナリオは高いです。主要企業は、顧客のアンメットニーズに応えるため、提携、新製品開発、合併、買収、地理的拡大など様々な戦略に取り組んでいます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 世界のヒトメタニューモウイルス診断市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/補助的な市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 世界のヒトメタニューモウイルス診断市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 世界のヒトメタニューモウイルス診断市場：技術別、推定・動向分析

• セグメントダッシュボード
• 世界のヒトメタニューモウイルス診断市場の技術変動分析
• 世界のヒトメタニューモウイルス診断市場の規模と動向分析、技術別、2018～2030年
• PCRベースの診断
• 次世代シーケンシング（NGS）
• 免疫蛍光アッセイ
• ラテラルフローアッセイ
• マイクロアレイ技術
• その他の先進技術

第5章 世界のヒトメタニューモウイルス診断市場：最終用途別、推定・動向分析

• セグメントダッシュボード
• 世界のヒトメタニューモウイルス診断市場の最終用途変動分析
• 世界のヒトメタニューモウイルス診断市場の規模と動向分析、最終用途別、2018～2030年
• 病院とクリニック
• 診断と参照検査室
• 学術研究機関
• その他

第6章 ヒトメタニューモウイルス診断市場：地域別、推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018～2030年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 企業/競合の分類
• 戦略マッピング
• 企業市況分析、2023年
• 主要な認証プロバイダー/スキーム所有者一覧
• 企業プロファイル/上場企業
  • QuidelOrtho Corporation
  • ARUP Laboratories
  • Diasorin
  • R-Biopharm AG
  • Seegene Inc.
  • ZeptoMetrix
  • Abbott
  • Thermo Fisher Scientific Inc.

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 Global Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 4 Global Human Metapneumovirus (hMPV) diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 5 Global Human Metapneumovirus (hMPV) diagnostics market, by region, 2018 - 2030 (USD Million)
• Table 6 North America Human Metapneumovirus (hMPV) diagnostics market, by country, 2018 - 2030 (USD Million)
• Table 7 North America Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 8 North America Human Metapneumovirus (hMPV) diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 9 U.S. Human Metapneumovirus (hMPV) diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 10 U.S. Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 11 Canada Human Metapneumovirus (hMPV) diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 12 Canada Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 13 Europe Human Metapneumovirus (hMPV) diagnostics market, by country, 2018 - 2030 (USD Million)
• Table 14 Europe Human Metapneumovirus (hMPV) diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 15 Europe Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 16 UK Human Metapneumovirus (hMPV) diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 17 UK Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 18 Germany Human Metapneumovirus (hMPV) diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 19 Germany Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 20 France Human Metapneumovirus (hMPV) diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 21 France Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 22 Italy Human Metapneumovirus (hMPV) diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 23 Italy Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 24 Spain Human Metapneumovirus (hMPV) diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 25 Spain Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 26 Sweden Human Metapneumovirus (hMPV) diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 27 Sweden Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 28 Denmark Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 29 Denmark Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 30 Norway Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 31 Norway Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 32 Asia Pacific Human Metapneumovirus (hMPV) diagnostics market, by country, 2018 - 2030 (USD Million)
• Table 33 Asia Pacific Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 34 Asia Pacific Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 35 Japan Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 36 Japan Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 37 India Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 38 India Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 39 China Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 40 China Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 41 Australia Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 42 Australia Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 43 South Korea Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 44 South Korea Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 45 Thailand Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 46 Thailand Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 47 Latin America Human Metapneumovirus (hMPV) diagnostics market, by country, 2018 - 2030 (USD Million)
• Table 48 Latin America Human Metapneumovirus (hMPV) diagnostics market, by end-use, 2018 - 2030 (USD Million)
• Table 49 Latin America Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 50 Brazil Human Metapneumovirus (hMPV) diagnostics market, by end-use types, 2018 - 2030 (USD Million)
• Table 51 Brazil Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 52 Mexico Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 53 Mexico Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 54 Argentina Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 55 Argentina Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 56 Middle East & Africa Human Metapneumovirus (hMPV) diagnostics market, by country, 2018 - 2030 (USD Million)
• Table 57 Middle East & Africa Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 58 Middle East & Africa Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 59 South Africa Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 60 South Africa Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 61 Saudi Arabia Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 62 Saudi Arabia Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 63 UAE Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 64 UAE Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)
• Table 65 Kuwait Human Metapneumovirus (hMPV) diagnostics market, by end-use type, 2018 - 2030 (USD Million)
• Table 66 Kuwait Human Metapneumovirus (hMPV) diagnostics market, by technology, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Human Metapneumovirus (hMPV) diagnostics market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Segment snapshot
• Fig. 11 Competitive landscape snapshot
• Fig. 12 Human Metapneumovirus (hMPV) diagnostics market driver analysis
• Fig. 13 Human Metapneumovirus (hMPV) diagnostics market restraint analysis
• Fig. 14 Human Metapneumovirus (hMPV) diagnostics market: Porter's analysis
• Fig. 15 Human Metapneumovirus (hMPV) diagnostics market: PESTLE analysis
• Fig. 16 Human Metapneumovirus (hMPV) diagnostics market: Technology outlook and key takeaways
• Fig. 17 Human Metapneumovirus (hMPV) diagnostics market: Technology market share analysis, 2024 - 2030
• Fig. 18 PCR-based diagnostics market, 2018 - 2030 (USD Million)
• Fig. 19 Next-Generation Sequencing (NGS) market, 2018 - 2030 (USD Million)
• Fig. 20 Immunofluorescence assays market, 2018 - 2030 (USD Million)
• Fig. 21 Lateral flow assays market, 2018 - 2030 (USD Million)
• Fig. 22 Microarray technology market, 2018 - 2030 (USD Million)
• Fig. 23 Other advanced technologies market, 2018 - 2030 (USD Million)
• Fig. 24 Human Metapneumovirus (hMPV) diagnostics market: End-use outlook and key takeaways
• Fig. 25 Human Metapneumovirus (hMPV) diagnostics market: End-use market share analysis, 2024 - 2030
• Fig. 26 Hospitals and clinics
• Fig. 27 Diagnostic and reference laboratories
• Fig. 28 Academic and research institutions
• Fig. 29 Others market, 2018 - 2030 (USD Million)
• Fig. 30 Regional marketplace key takeaways
• Fig. 31 North America Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 U.S. Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 U.S. key country dynamics
• Fig. 34 Canada Human Metapneumovirus (hMPV) diagnostics market, 2018 - 2030 (USD Million)
• Fig. 35 Canada key country dynamics
• Fig. 36 Mexico Human Metapneumovirus (hMPV) diagnostics market, 2018 - 2030 (USD Million)
• Fig. 37 Mexico key country dynamics
• Fig. 38 Europe Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 UK Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 UK key country dynamics
• Fig. 41 Germany Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Germany key country dynamics
• Fig. 43 France Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 France key country dynamics
• Fig. 45 Italy Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 46 Italy key country dynamics
• Fig. 47 Spain Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 48 Spain key country dynamics
• Fig. 49 Denmark Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 50 Denmark key country dynamics
• Fig. 51 Sweden Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 52 Sweden key country dynamics
• Fig. 53 Norway Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 54 Norway key country dynamics
• Fig. 55 Asia-Pacific Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 56 Japan Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 57 Japan key country dynamics
• Fig. 58 China Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 59 China key country dynamics
• Fig. 60 India Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 61 India key country dynamics
• Fig. 62 Australia Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 63 Australia key country dynamics
• Fig. 64 Thailand Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 65 Thailand key country dynamics
• Fig. 66 South Korea Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 67 South Korea key country dynamics
• Fig. 68 Latin America Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 69 Brazil Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 70 Brazil key country dynamics
• Fig. 71 Argentina Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 72 Argentina key country dynamics
• Fig. 73 MEA Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 74 South Africa Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 75 South Africa key country dynamics
• Fig. 76 Saudi Arabia Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 77 Saudi Arabia key country dynamics
• Fig. 78 UAE Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 79 UAE key country dynamics
• Fig. 80 Kuwait Human Metapneumovirus (hMPV) diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 81 Kuwait key country dynamics
• Fig. 82 Key company categorization
• Fig. 83 Company market share analysis
• Fig. 84 Company market position analysis
• Fig. 85 Market participant categorization
• Fig. 86 Strategy framework

Human Metapneumovirus Diagnostics Market Growth and Trends:

The global human metapneumovirus diagnostics market size is anticipated to reach USD 971.30 million by 2030 and is projected to grow at a CAGR 10.43% from 2025 to 2030, according to a new report by Grand View Research, Inc. The human metapneumovirus (hMPV) diagnostics market is experiencing significant growth, driven by the increasing prevalence of respiratory infections caused by hMPV, particularly among vulnerable populations such as children, the elderly, and immunocompromised individuals. hMPV is known to cause respiratory illnesses similar to those caused by influenza and respiratory syncytial virus (RSV), including bronchiolitis, pneumonia, and upper respiratory tract infections. As awareness about hMPV's role in respiratory diseases increases, there is a growing demand for effective diagnostic solutions, contributing to the market's expansion.

Key drivers of this market include advancements in diagnostic technologies, rising healthcare spending, and the growing demand for early and accurate detection of hMPV infections. The increasing prevalence of viral respiratory infections, especially in regions with temperate climates, is also a significant factor propelling growth. Furthermore, the ongoing development of rapid diagnostic tests, such as PCR-based assays, antigen-based tests, and multiplex PCR platforms, enables faster detection, which is crucial for improving patient outcomes and controlling the spread of infections.

The hMPV diagnostics market is highly competitive, with several prominent players contributing to its growth. Key market participants include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, BioMerieux, and Siemens Healthineers. These companies are actively involved in developing new diagnostic tools and platforms to detect hMPV more efficiently. Strategic collaborations, acquisitions, and research and development investments are helping them expand their product portfolios and increase their presence.

Recent market trends highlight a shift towards more sophisticated, rapid, and cost-effective diagnostic methods, such as point-of-care testing and multiplex molecular tests that can detect multiple pathogens simultaneously. These innovations are critical in addressing the growing demand for efficient diagnostics, particularly in resource-limited settings. The market is also witnessing an increased focus on developing tests that provide faster results to aid in timely treatment decisions, which is essential for high-risk patient groups.

Prevalence rates of hMPV infections are rising globally, especially in children under five years of age, as well as in the elderly and those with weakened immune systems. The virus is responsible for a substantial number of respiratory hospitalizations, making it a significant public health concern. Accurate and timely diagnosis is crucial for effective management, and the growing adoption of diagnostic solutions is expected to continue to shape the future of the hMPV diagnostics market.

Human Metapneumovirus (hMPV) Diagnostics Market Report Highlights:

• Based on technology, PCR-based diagnostics segment held the largest revenue share of 54.97% in 2024, driven by its high accuracy, sensitivity, and ability to detect low viral loads. PCR assays enable rapid, reliable detection of hMPV, even in early stages of infection, leading to faster diagnosis, better patient outcomes, and enhanced control of viral transmission, especially in high-risk populations.
• Based on end use, diagnostic and reference laboratories segment is expected to grow at the fastest CAGR over the forecast period driven by increasing demand for specialized testing, faster diagnostic results, and more accurate disease detection. These laboratories provide essential services for identifying hMPV and other respiratory infections, supporting both clinical and research settings.
• Based on region, North America market dominated the overall global market and accounted for the 41.18% revenue share in 2024 driven by the increasing due to higher awareness, advanced healthcare infrastructure, and increased prevalence of respiratory infections.
• The competitive scenario in the Human Metapneumovirus (hMPV) diagnostics market is high. The major companies are undertaking various strategies such as collaborations, new product development, mergers, acquisitions, and geographic expansion for serving the unmet needs of their customers.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Technology Segment
  • 1.2.2. End-use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Global Human Metapneumovirus (hMPV) Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of respiratory infections
    • 3.2.1.2. Advancements in molecular diagnostic
    • 3.2.1.3. Growing awareness among healthcare providers
    • 3.2.1.4. Supportive regulatory approvals and guidelines
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High costs of advanced diagnostics tests
    • 3.2.2.2. Limited awareness in developing regions
• 3.3. Global Human Metapneumovirus (hMPV) Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Global Human Metapneumovirus (hMPV) Diagnostics Market: Technology Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Human Metapneumovirus (hMPV) Diagnostics Market Technology Movement Analysis
• 4.3. Global Human Metapneumovirus (hMPV) Diagnostics Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 4.4. PCR-Based Diagnostics
  • 4.4.1. PCR-based diagnostics market estimates and forecast, 2018 - 2030 (USD Million)
• 4.5. Next-Generation Sequencing (NGS)
  • 4.5.1. Next-Generation Sequencing (NGS) market estimates and forecast, 2018 - 2030 (USD Million)
• 4.6. Immunofluorescence Assays
  • 4.6.1. Immunofluorescence assays market estimates and forecast, 2018 - 2030 (USD Million)
• 4.7. Lateral Flow Assays
  • 4.7.1. Lateral flow assays market estimates and forecast, 2018 - 2030 (USD Million)
• 4.8. Microarray Technology
  • 4.8.1. Microarray technology market estimates and forecast, 2018 - 2030 (USD Million)
• 4.9. Other Advanced Technologies
  • 4.9.1. Other advanced technologies market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5. Global Human Metapneumovirus (hMPV) Diagnostics Market: End-use Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Human Metapneumovirus (hMPV) Diagnostics Market End-use Movement Analysis
• 5.3. Global Human Metapneumovirus (hMPV) Diagnostics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 5.4. Hospitals and Clinics
  • 5.4.1. Hospitals and clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Diagnostic and Reference Laboratories
  • 5.5.1. Diagnostic and reference laboratories market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Academic and Research Institutions
  • 5.6.1. Academic and research institutions market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Human Metapneumovirus (hMPV) Diagnostics Market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Strategy Mapping
• 7.3. Company Market Position Analysis, 2023
• 7.4. List of Key Certification Providers/Scheme Owners
• 7.5. Company Profiles/Listing
  • 7.5.1. QuidelOrtho Corporation
    • 7.5.1.1. Company overview
    • 7.5.1.2. Financial performance
    • 7.5.1.3. Product benchmarking
    • 7.5.1.4. Strategic initiatives
  • 7.5.2. ARUP Laboratories
    • 7.5.2.1. Company overview
    • 7.5.2.2. Financial performance
    • 7.5.2.3. Product benchmarking
    • 7.5.2.4. Strategic initiatives
  • 7.5.3. Diasorin
    • 7.5.3.1. Company overview
    • 7.5.3.2. Financial performance
    • 7.5.3.3. Product benchmarking
    • 7.5.3.4. Strategic initiatives
  • 7.5.4. R-Biopharm AG
    • 7.5.4.1. Company overview
    • 7.5.4.2. Financial performance
    • 7.5.4.3. Product benchmarking
    • 7.5.4.4. Strategic initiatives
  • 7.5.5. Seegene Inc.
    • 7.5.5.1. Company overview
    • 7.5.5.2. Financial performance
    • 7.5.5.3. Product benchmarking
    • 7.5.5.4. Strategic initiatives
  • 7.5.6. ZeptoMetrix
    • 7.5.6.1. Company overview
    • 7.5.6.2. Financial performance
    • 7.5.6.3. Product benchmarking
    • 7.5.6.4. Strategic initiatives
  • 7.5.7. Abbott
    • 7.5.7.1. Company overview
    • 7.5.7.2. Financial performance
    • 7.5.7.3. Product benchmarking
    • 7.5.7.4. Strategic initiatives
  • 7.5.8. Thermo Fisher Scientific Inc.
    • 7.5.8.1. Company overview
    • 7.5.8.2. Financial performance
    • 7.5.8.3. Product benchmarking
    • 7.5.8.4. Strategic initiatives